Sandrine Mansard

Clermont-ferrand, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Impact of melanoma histological regression on first-line immunotherapy response in stage-IV disease.

Impact of melanoma histological regression on first-line immunotherapy response in stage-IV disease.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 11, 2025

Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.

Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 12, 2025

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).

Journal: The British journal of dermatology

Published: December 10, 2024

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.

Journal: The Lancet. Oncology

Published: October 23, 2024

Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial.

Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 20, 2024

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.

Journal: ESMO open

Published: August 09, 2023

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Journal: Journal of neurology

Published: August 06, 2023

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 12, 2023

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 06, 2023

Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.

Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.

Journal: Melanoma research

Published: March 30, 2023

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Journal: Annales de dermatologie et de venereologie

Published: February 07, 2023

Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).

Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).

Journal: PloS one

Published: January 10, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026